SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to a new 52-week high and bullish call-option activity are drawing attention ahead of the expected Q3 report, with traders watching BRIUMVIs sales momentum and guidance. Buyout speculation is adding to the excitement, but remains unconfirmed; some investors see the move as earnings positioning while others question whether expectations are already priced in.

Root, Inc. is a technology insurance company, which engages in the provision of insurance services. It offers mobile telematics and technology platforms to segment individual risk based on complex behavioral data and customer experience to make pricing decisions and grow businesses. It provides insurance products and services in the United States. The company was founded by Alexander E. Timm and Daniel Manges in February 2015 and is headquartered in Columbus, OH.

Root Inc - Ordinary Shares - Class A

Root Inc

Roots Hyundai Secure+ white-label insurance offering is drawing attention, with traders viewing the dealership channel as a potential source of policy growth while others question how quickly it will convert into business. The debate is set against concern about recent declines in policies in force and sluggish revenue growth, despite continued profitability.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

OXYs breakout to a six-month high and call-heavy options activity have drawn attention, alongside optimism that debt reduction and stronger free cash flow are improving the oil producers outlook. Traders are split between expecting further momentum and cautioning that the shares could stall after lagging crude at times.

Cheniere Energy, Inc. engages in liquefied natural gas (LNG) related businesses. It owns and operates LNG terminals, develops, constructs, and operates liquefaction projects near Corpus Christi, Texas, and at the Sabine Pass LNG terminal. The company was founded by Charif Souki in 1983 and is headquartered in Houston, TX.

Cheniere Energy Inc.

Chenieres strong Q3 results, raised full-year guidance, dividend increase, and completion of its Corpus Christi expansion are driving attention as shares reach a new high. Many traders are bullish on the operating momentum, while some are taking profits or pointing to put-heavy options activity and the risk of a pause after the run-up.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Regeneron is drawing attention after a third-quarter earnings beat, with growth in Dupixent and Eylea HD helping offset pressure on legacy Eylea. Traders largely welcomed the results and sharp share move, while some question whether newer products can sustain growth amid biosimilar competition.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Stockholm, Sweden.

Spotify Technology S.A.

Spotifys latest quarterly report has driven attention: despite revenue and earnings coming in below expectations, subscriber growth, stronger gross margins, and a better-than-expected next-quarter profit outlook have been credited for the stocks sharp rise. Traders are debating the disconnect between the headline miss and the upbeat guidance, with some questioning whether higher expenses and the recent run-up make the rally sustainable.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLakes BLA filing for sonelokimab in hidradenitis suppurativa and the pending FDA acceptance and review-timeline decision are the main focus, with traders debating whether regulatory progress can revive the stock. Bulls point to the clinical data and commercial potential, while bears emphasize approval risk and the costs of launching alone; buyout talk remains speculative.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Positive Phase 3 data for Amgens cancer and Sjgrens disease programs are reinforcing bullish momentum as the shares approach highs. Traders are also focused on upcoming quarterly results, with some viewing put activity as earnings protection rather than a bearish bet.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is drawing attention as traders position for further Nasdaq weakness, citing tech and AI-spending concerns alongside market volatility. Some expect a deeper selloff, while others warn that reports of a possible U.S.-Iran deal and Strait of Hormuz reopening could fuel a rebound and hurt short positions.

OFFICIAL TRUMP (TRUMP) is a cryptocurrency and operates on the Solana platform. OFFICIAL TRUMP has a current supply of 999,998,811.032761 with 281,866,747.320393 in circulation. The last known price of OFFICIAL TRUMP is 1.57555883 USD and is down -1.93 over the last 24 hours. It is currently trading on 744 active market(s) with $126,884,732.61 traded over the last 24 hours. More information can be found at https://gettrumpmemes.com/.

Trump For President

The Trump-branded meme coin is drawing attention amid discussion of its steep decline and retail holders losses, with many traders calling it a cash grab. A smaller bullish contingent points to the recent bounce and speculates about an election-linked rebound or short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gilead Sciences (GILD) Q3 Earnings and Revenues Top Estimates

Gilead (GILD) delivered earnings and revenue surprises of +17.51% and +6.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline

Tarsus Pharmaceuticals (TARS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates

Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of -104.76% and +5.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Agenus (AGEN) Earnings Expected to Grow: Should You Buy?

Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy

Tarsus Pharmaceuticals (TARS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Tarsus Pharmaceuticals (TARS) Moves 7.5% Higher: Will This Strength Last?

Tarsus Pharmaceuticals (TARS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme

Equity

Culper’s central allegation is that Tarsus has driven XDEMVY uptake among Medicare patients by funding copay assistance. 


Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research published a report Wednesday alleging the company's sole commercial product relies on an illegal Medicare copay scheme. Here's what you should know.read more...

Tarsus Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. It is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the potential prevention of Lyme disease. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Tarsus Pharmaceuticals Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Culper also alleged that Tarsus inflated its total addressable market estimate. &nbsp;</li><li>The firm further asserts that Tarsus will miss 2026 guidance.</li><li>Retail traders dismissed Culper’s claims, highlighting its past record of shorting Praxis Precision and Axsome Therapeutics.</li></ul>Tarsus Pharmaceuticals (TARS) shares fell about 5% on Wednesday after short seller Culper Research revealed its short position in the stock and published a detailed report accusing the company of using questionable practices to drive sales of its sole product, XDEMVY.The stock is now on track to clock its worst day since April.<h2 class="st-heading-2">Alleged Medicare Copay Scheme</h2>Culper’s central allegation is that Tarsus has driven XDEMVY uptake among Medicare patients by funding copay assistance through the HealthWell Foundation’s blepharitis fund, launched in September 2023— shortly after XDEMVY’s approval. The report claims Tarsus donations, $5.7 million in 2023 and $31.2 million in 2024, closely match the fund’s total receipts, suggesting Tarsus is effectively the sole major donor.This structure, Culper argues, violates the Anti-Kickback Statute (AKS). Similar copay schemes have led to large DOJ settlements.The report notes that Tarsus previously disclosed “patient assistance donations” in its earnings as selling, general, and administrative costs before reclassifying the spending. One specialty pharmacy reportedly steers Medicare patients to the fund, and Culper claims 50% of Medicare XDEMVY patients use it.XDEMVY is the first and only FDA-approved prescription eye drop designed to directly target and kill Demodex mites, the root cause of Demodex blepharitis. It is Tarsus’s sole commercial product.<h2 class="st-heading-2">Inflated Total Addressable Market</h2>Tarsus has touted a 25 million U.S. patient opportunity for Demodex blepharitis, implying peak XDEMVY sales above $2 billion. Culper calls this “wildly inflated.” A survey of 30 current prescribers found only 18% of their patients had the condition, implying a true total addressable market closer to 5 million.The report contends that Tarsus equates any collarettes, common even in healthy people, with clinical disease and downplays that XDEMVY is a one-time six-week course with limited retreatment. Tarsus has already treated roughly 600,000 of the 1.5 million ever-diagnosed patients. Culper estimates peak annual revenues below $800 million.Financial Miss LikelyCulper asserts Tarsus will miss 2026 guidance. “Patient assistance” and other SG&amp;A costs are rising sharply and are under-modeled by analysts. Consensus forecasts remain too optimistic, the report says, pointing to ballooning expenses hidden in legal and IT lines.<h2 class="st-heading-2">How Did TARS Retail Traders React?</h2>On Stocktwits, retail sentiment around TARS stock fell from bullish to neutral territory over the past 24 hours, while message volume stayed at high levels.A Stocktwits user refuted Culper’s claims of a small total addressable market for XDEMVY.<stembedurl>https://www.stocktwits.com/Biotechace/message/658074096</stembedurl>Another user highlighted Culper’s<a href="https://stocktwits.com/news-articles/markets/equity/praxis-precision-medicines-stock-drops-after-culper-research-reveals-short-position/cLPAFl6REaV"> track record</a>, previously shorting Praxis Precision and Axsome Therapeutics, both of which are trading at significant premiums since.<stembedurl>https://www.stocktwits.com/CH_Expat/message/658071922</stembedurl><a href="https://stocktwits.com/symbol/TARS">TARS stock</a> has fallen 26% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/rivian-ceo-flags-memory-chip-shortage-risk-for-r2-production-retail-eyes-q2-delivery-numbers/cZm3NOgR71X">Rivian CEO Flags Memory Chip Shortage Risk For R2 Production – Retail Eyes Q2 Delivery Numbers</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Tarsus Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Culper’s central allegation is that Tarsus has driven XDEMVY uptake among Medicare patients by funding copay assistance. 

Axsome Therapeutics Inc

iShares Russell 2000 ETF

Praxis Precision Medicines Inc

Vanguard Total Stock Market ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

TARS News